Oral bisphosphonates and risk of subtrochanteric or diaphyseal femur fractures in a population-based cohort
Authors:
Open Access
- 18 November 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 26 (5) , 993-1001
Abstract
Bisphosphonates are the primary therapy for postmenopausal and glucocorticoid-induced osteoporosis. Case series suggest a potential link between prolonged use of bisphosphonates and low-energy fracture of subtrochanteric or diaphyseal femur as a consequence of oversuppression of bone resorption. Using health care utilization data, we conducted a propensity score–matched cohort study to examine the incidence rates (IRs) and risk of subtrochanteric or diaphyseal femur fractures among oral bisphosphonate users compared with raloxifene or calcitonin users. A Cox proportional hazards model evaluated the risk of these fractures associated with duration of osteoporosis treatment. A total of 104 subtrochanteric or diaphyseal femur fractures were observed among 33,815 patients. The estimated IR of subtrochanteric or diaphyseal femur fractures per 1000 person-years was 1.46 [95% confidence interval (CI) 1.11–1.88] among the bisphosphonate users and 1.43 (95% CI 1.06–1.89) among raloxifene/calcitonin users. No significant association between bisphosphonate use and subtrochanteric or diaphyseal femur fractures was found [hazard ratio (HR) = 1.03, 95% CI 0.70–1.52] compared with raloxifene/calcitonin. Even with this large study size, we had little precision in estimating the risk of subtrochanteric or diaphyseal femur fractures in patients treated with bisphosphonates for longer than 5 years (HR = 2.02, 95% CI 0.41–10.00). The occurrence of subtrochanteric or diaphyseal femur fracture was rare. There was no evidence of an increased risk of subtrochanteric or diaphyseal femur fractures in bisphosphonate users compared with raloxifene/calcitonin users. However, this study cannot exclude the possibility that long-term bisphosphonate use may increase the risk of these fractures. © 2011 American Society for Bone and Mineral Research.Keywords
This publication has 31 references indexed in Scilit:
- A basic study design for expedited safety signal evaluation based on electronic healthcare dataPharmacoepidemiology and Drug Safety, 2010
- Low-Energy Femoral Fractures Associated with the Long-Term Use of BisphosphonatesDrug Safety, 2009
- Incidence of stress fractures of the femoral shaft in women treated with bisphosphonateActa Orthopaedica, 2009
- Bisphosphonates: Mechanism of Action and Role in Clinical PracticeMayo Clinic Proceedings, 2008
- More on Atypical Fractures of the Femoral DiaphysisNew England Journal of Medicine, 2008
- Low-Energy Femoral Shaft Fractures Associated With Alendronate UseJournal of Orthopaedic Trauma, 2008
- Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial ResultsMedical Care, 2007
- Checking the Cox model with cumulative sums of martingale-based residualsBiometrika, 1993
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978